aspr

HHS Allocates Regeneron Therapeutic to Treat Patients with Mild to Moderate COVID-19

 

 

[advanced_iframe src=”https://view.connect.hhs.gov/?qs=6a12b90952c3e6e9e834e5eafcc491ae0266fdc37e67fbcb6aeae29df1128cda5139fd9d5326cece76584ef20f07f9623c3cff9e771796d364af1f9a87b6475b185df7cdb99508a1″ width=”100%” height=”2600″]